![](/img/cover-not-exists.png)
P408 Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
van Hoeve, K, Dreesen, E, Hoffman, I, Ferrante, M, Gils, A, Vermeire, SVolume:
13
Language:
english
Journal:
Journal of Crohn's and Colitis
DOI:
10.1093/ecco-jcc/jjy222.532
Date:
January, 2019
File:
PDF, 222 KB
english, 2019